Back

Longitudinal changes in amyloid burden as measured by extracellular volume (ECV) on cardiac MRI for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)

28 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Cardiac magnetic resonance of amyloidosis and myocardial remodelling Extracellular Volume ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Margaret O'Neill-Dee

Massachusetts General Hospital - Harvard Medical School, Boston (United States of America)

7 More presentations in this session

Presentation thumbnail
Long-term improvement in myocardial structure and function in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis compared with a natural history cohort
Doctor A. Sheikh (London, GB)
Abstract Slides Video
Presentation thumbnail
Left ventricular remodelling index: Reference ranges and prognostic associations in 44,000 UK Biobank participants
Doctor R. Roy (London, GB)
Abstract Slides Video
Presentation thumbnail
Proteome-wide mendelian randomization identifies circulating proteins influencing cardiac structure and function
Doctor R. Roy (London, GB)
Abstract Slides Video
Presentation thumbnail
Characteristics and clinical significance of myocardial work in cardiac light-chain amyloidosis: pressure-volume loop analysis based on cardiac magnetic resonance
Doctor S. Liang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Cardiometabolic myocardial remodelling across the glycaemic spectrum: a multi-level meta-analysis of CMR T1 mapping and extracellular volume
Doctor A. Dharan (Melbourne, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac magnetic resonance of amyloidosis and myocardial remodelling

The Event

Event poster

ESC Congress 2026

28 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Evolution over time of cardiac biomarkers, electrocardiographic and echocardiographic features in a large cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis
31 August 2024
thumbnail
Congress Presentation
CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathy
28 August 2026
thumbnail
Congress Presentation
Decoding the decades: Tafamidis efficacy across different age groups in ATTR-CM patients
19 May 2025
thumbnail
Congress Presentation
Characteristics and treatment of contemporary real-world patients with cardiac transthyretin amyloidosis: a retrospective, multicenter, observational study
11 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources